TRAMADOL HYDROCHLORIDE


Trade Names	CONZIP RYBIX ODT RYZOLT TRAMADOL HYDROCHLORIDE ULTRAM ULTRAM ER
Synonyms	Aceon Amadol CG-315 CG-315E Contramal Conzip Dromadol sr Dromadol xl Invodol sr Larapam sr Mabron Maneo Marol Maxitram sr NIH-10969 NSC-759105 Nobligan ret Oldaram Qdolo Rybix odt Ryzolt Tilodol sr Tradonal Tradorec xl Tramacet Tramadol hcl Tramadol hydrochloride Tramadol hydrochloride civ Tramake Tramake insts Tramal Tramquel sr Tramulief sr U-26,225A U-26225A Ultram Ultram er Zamadol Zamadol 24hr Zamadol melt Zamadol sr Zamudol Zeridame sr Zertane Zydol Zydol sr Zydol xl
Status
Molecule Category	Salt-form
UNII	9N7R477WCK
Parent Compound:	TRAMADOL


Active Pharmaceutical Ingredients Bioactive chemicals	Exact Similarity SubStructure	Threshold (%) >= 70

Structure


InChI Key	PPKXEPBICJTCRU-UHFFFAOYSA-N
Smiles	COc1cccc(C2(O)CCCCC2CN(C)C)c1.Cl
InChI	InChI=1S/C16H25NO2.ClH/c1-17(2)12-14-7-4-5-10-16(14,18)13-8-6-9-15(11-13)19-3;/h6,8-9,11,14,18H,4-5,7,10,12H2,1-3H3;1H

Physicochemical Descriptors

Property Name	Value
Molecular Formula	C16H26ClNO2
Molecular Weight	299.84
AlogP	2.63
Hydrogen Bond Acceptor	3.0
Hydrogen Bond Donor	1.0
Number of Rotational Bond	4.0
Polar Surface Area	32.7
Molecular species	BASE
Aromatic Rings	1.0
Heavy Atoms	19.0

Bioactivity

Mechanism of Action	Action	Reference
Mu opioid receptor agonist	AGONIST	FDA


Protein: Mu opioid receptor Description: Mu-type opioid receptor Organism : Homo sapiens P35372 ENSG00000112038

Cross References

Resources	Reference
ChEBI	75725
ChEMBL	CHEMBL1237065
FDA SRS	9N7R477WCK
PubChem	63013
SureChEMBL	SCHEMBL405855
ZINC	ZINC00000853

CONTENTS


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).